US Patent

US12036290 — Pharmaceutical formulations

Method of Use · Assigned to Blue Earth Diagnostics Ltd · Expires 2041-11-27 · 16y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a pharmaceutical composition containing a radiohybrid agent with specific components and pH range.

USPTO Abstract

The present invention relates to a pharmaceutical composition comprising a radiohybrid agent containing a silicon-fluoride and a chelating group wherein either the fluorine is 18 F or the chelating group contains a chelated radioactive metal, wherein the composition has a pH of 4.0-6.0 and further comprises: 0.1-200 mM citrate buffer; 1-100 mg/mL ethanol; and 5-10 mg/mL sodium chloride.

Drugs covered by this patent

Posluma (FLOTUFOLASTAT F-18 GALLIUM) · Blue Earth

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3614`	—	Posluma

Patent Metadata

Patent number: US12036290
Jurisdiction: US
Classification: Method of Use
Expires: 2041-11-27
Drug substance claim: No
Drug product claim: Yes
Assignee: Blue Earth Diagnostics Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.